You are here

  • Home
  • Archive
  • Volume 27, Issue S5
  • Meeting Report From the 2016 11th Biennial Ovarian Cancer Research Symposium: Mechanisms of Initiation and Progression of Ovarian Cancers

Article Text

Article menu
Download PDFPDF
Rivkin Symposium
Meeting Report From the 2016 11th Biennial Ovarian Cancer Research Symposium: Mechanisms of Initiation and Progression of Ovarian Cancers
  1. Jeremy Chien, PhD* and
  2. Geeta Mehta, PhD†
  1. *Department of Cancer Biology, University of Kansas Medical Center, Kansas City, KS; and
  2. †Departments of Materials Science and Engineering, and Biomedical Engineering, Macromolecular Science and Engineering, University of Michigan, Ann Arbor, MI.
  1. Address correspondence and reprint requests to Geeta Mehta, PhD, Department of Biomedical Engineering, Macromolecular Science and Engineering University of Michigan, North Campus Research Complex (NCRC), 2800 Plymouth Rd, Building 28, Room 3044 W, Ann Arbor, MI 48109–2800. E-mail: mehtagee@umich.edu.

Abstract

Objective The aim of this study was to review the latest research advances on the mechanisms of initiation and progression of ovarian cancer.

Methods At the 11th Biennial Ovarian Cancer Research Symposium, which was held in Seattle, Washington in September 2016, leaders in ovarian cancer research convened to present and discuss current advances and future directions in ovarian cancer research.

Results One session was dedicated to Mechanisms of Initiation and Progression of Ovarian Cancer, and included a keynote presentation from Dr Ronny Drapkin, MD (University of Pennsylvania), and an invited oral presentation from Laising Yen, PhD (Baylor College of Medicine). Nine additional oral presentations were selected from abstract submissions. Thirty-three abstracts were presented in poster format and were grouped into the categories of mechanisms of the genesis of genomic instability, tumor initiation, metastases of ovarian cancers, innate and acquired chemotherapy resistance, tumor progression, tumor-initiating cell and chemotherapy resistance, and immunomodulation.

Conclusions Eradication of ovarian cancers requires clear understanding of molecular mechanisms of ovarian cancer initiation and progression. These mechanisms will not only drive the precision of early detection, but also discovery of new therapies to target precursor lesions and more advanced stage disease.

  • 11th Biennial Ovarian Cancer Research Symposium
  • Initiation
  • Progression
  • Ovarian cancer
  • Genomics
  • Precursor lesions

https://doi.org/10.1097/IGC.0000000000001117

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Footnotes

    • This work was supported by the DOD OCRP Early Career Investigator Award W81XWH-13-1-0134 (GM) and DOD OCRP Early Career Investigator Award W81XWH-10-1-0386 (JC).

    • The authors declare no conflicts of interest.